In December 2025, the Danish Healthcare Quality Institute (DHQI) released a methodological document clarifying the processes of health economic analyses associated with the clinical guidelines and the DHQI Council’s decision-making. Furthermore, the first two health economic analyses associated with the clinical guidelines were published concerning prostate-specific membrane antigen (PSMA)-PET/CT in prostate cancer and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.